GLP-1 Tirzepatide ReviewS.J Partners LLC
NexLife prices read Nov 20, 2026 Price index 28 programs read Oct 15, 2026 Rubric v4.1 Corrections open log

Head to head

Enhance.MD vs Henry Meds: Pricing, Evidence and What Neither Discloses

$169 against $179 is a 6% difference between two figures neither of which we captured ourselves. That gap is smaller than the uncertainty in the figures, so we do not call a winner.

Direct answer

On their own pages, read November 20, 2026 or later, Enhance.MD lists $329 month to month and $280 at its lowest (48-week term); Henry Meds prints no compounded tirzepatide price on the pages we read, so there is no like-for-like tirzepatide price comparison. On our written v4.1 scoring guide, Enhance.MD scores 79/100 (#3 of 22) and Henry Meds scores 50/100 (#18 of 22).

Answer last reviewed:

The short answer

$169 against $179 is a 6% difference between two figures neither of which we captured ourselves. That gap is smaller than the uncertainty in the figures, so we do not call a winner. Both figures are provider-reported.

Price is one of five fields that matter, and it is the only one either company reliably publishes. The others — which pharmacy fills the prescription, whether the price holds as your dose rises, what is refunded if you stop, and whether the programme can lawfully serve your state — are unverified for both.

Compare at a maintenance dose, not at signup

The tirzepatide label describes 2.5 mg as treatment initiation and states it is not approved as a maintenance dosage. You take it for four weeks and then never again. Where a programme tiers by dose, the advertised figure is usually that starting dose — so a comparison built on it ranks these two on a price neither charges after month one.

Ask both for the all-in monthly cost at 10 mg, which is a recommended maintenance dosage, and compare those.

What neither has told us

Neither Enhance.MD nor Henry Meds has named its fulfilling pharmacy or its registration class. That is true of most providers in our dataset (NexLife’s plan pages do name three 503A pharmacies), and it is the question we would put first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.

The comparison that outranks both

Check insurance first. Where a commercial plan covers Zepbound or Wegovy the cost can be near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until the end of 2027. Both sit below every self-pay route including every compounded programme in our dataset.

Failing that, brand Zepbound is $299 to $449 direct from LillyDirect and both approved oral GLP-1s start at $149 — figures worth having in front of you before choosing between two compounded programmes.

Enhance.MD against Henry Meds, lowest figure we hold by molecule
TirzepatideEnhance.MD $169Henry Meds $349SemaglutideEnhance.MD $212Henry Meds $179Enhance.MDHenry Meds
Show this figure as a table
Data table
ItemEnhance.MDHenry Meds
Tirzepatide$169$349
Semaglutide$212$179
Hatched bars mean we hold no figure at all for that molecule from that provider. A dashed edge means the figure is provider-reported rather than captured by us, so the bar is only as reliable as the provider’s own published number. A solid bar is a figure we read at the source ourselves.
Same fields, both providers
Same fields, both providers
FieldEnhance.MDHenry Meds
Lowest captured all-in$169/mo$179/mo
Lowest tirzepatide$169/mo$349/mo
Lowest semaglutide$212/mo$179/mo
Records we hold35
Evidence statusProvider-reported Provider-reportedProvider-reported Provider-reported
Fulfilling pharmacy named to usnono
Registration class disclosednono
State availability verifiednono
Cancellation terms capturednot verifiednot verified
Unverified rows are shown rather than dropped. A field omitted for one side is how a comparison picks a winner without appearing to.
Every captured record for Enhance.MD and Henry Meds
ProviderProgramFormulationDose coverageMedicationRequired feesAll-in monthlyPrice typeEvidenceCaptured
Enhance.MDprepaidcompounded microdosenot recorded$169not verified$169Commitment tierProvider-reported2026-07-06
Henry Medsmonth_to_monthcompounded sublingualnot recorded$179not verified$179RecurringProvider-reported2026-07-06
Henry Medsmonth_to_monthcompounded injectablenot recorded$179not verified$179RecurringProvider-reported2026-07-06
Enhance.MDprepaidcompounded injectablenot recorded$212not verified$212Commitment tierProvider-reported2026-07-06
Henry Medsprepaidcompounded oral / ODTnot recorded$249not verified$249Commitment tierProvider-reported2026-07-06
Enhance.MDprepaidcompounded injectablenot recorded$280not verified$280Commitment tierProvider-reported2026-07-06
Henry Medsmonth_to_monthcompounded injectablenot recorded$297not verified$297RecurringProvider-reported2026-07-06
Henry Medsprepaidcompounded oral / ODTnot recorded$349not verified$349Commitment tierProvider-reported2026-07-06

Our editorial pick, NexLife, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan (as of November 20, 2026), the same price at every dose with no membership fee. See NexLife’s current plans.

Questions readers actually ask

Is Enhance.MD cheaper than Henry Meds?

On their own pages, read November 20, 2026 or later, Enhance.MD lists $329 month to month and $280 at its lowest (48-week term); Henry Meds prints no compounded tirzepatide price on the pages we read, so there is no like-for-like tirzepatide price comparison.

Why is one marked verified and the other reported?

On our written v4.1 scoring guide, Enhance.MD scores 79/100 (#3 of 22) and Henry Meds scores 50/100 (#18 of 22). The scores come from each program’s own pages and FDA’s warning-letter index, read November 20–21, 2026.

Does either name its pharmacy?

Enhance.MD: Names its partner pharmacies on its FAQ; tirzepatide ‘compounded in accordance with federal Section 503A’. Henry Meds: ‘A 503(A) Compounding Pharmacy or 503(B) Outsourcing Facility’; none named.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Review. “Enhance.MD vs Henry Meds: Pricing, Evidence and What Neither Discloses.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/compare/enhance-md-vs-henry-meds/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Report an error
Comparing 0 of 4